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Abstract
Purpose In the study of (E7080) lenvatinib in differentiated
cancer of the thyroid, most patients experienced an adverse
event. In this report, we examine common lenvatinib-
emergent adverse events in this phase three, randomized,
double-blind study.
Methods Adverse events were graded per Common Ter-
minology Criteria for Adverse Events v4.0. 392 patients
were enrolled (lenvatinib: 261, placebo: 131) and received
lenvatinib 24 mg/day or placebo. The main outcome
measures were: associations with progression-free
survival and overall survival in exploratory
univariate and multivariate analyses along with additional
variables.
Results The most common any-grade adverse events (any
grade; grade 3) in lenvatinib-treated patients included
proteinuria (32%; 10%), diarrhea (67%; 9%), fatigue/
asthenia/malaise (67%; 10%), rash (23%; 0.4%), and
palmar-plantar erythrodysesthesia syndrome (33%; 3%).
There were no grade 4 events for these adverse events.
They generally occurred early (median time to ﬁrst onset
[weeks]: proteinuria [6.1], diarrhea [12.1], fatigue/asth-
enia/malaise [3.0], rash [7.3], and palmar-plantar ery-
throdysesthesia syndrome [5.9]), and were resolved
primarily with dose modiﬁcations (median time to reso-
lution [weeks]: proteinuria [8.8], diarrhea [18.1], fatigue/
asthenia/malaise [16.3], rash [5.9], and palmar-plantar
erythrodysesthesia syndrome [20.0]). Discontinuation
due to these adverse events occurred in 2 (1%) patients
with proteinuria and 4 (2%) with fatigue. Progression-
free survival was not associated with any of the adverse
events. Eastern Cooperative Oncology Group perfor-
mance status (P= 0.001), follicular histology (P=
0.002), and diarrhea (P= 0.023) were associated with
overall survival in multivariate analyses (median overall
survival for patients with diarrhea: not reached; without:
17.1 months).
Conclusions In the study of (E7080) lenvatinib in differ-
entiated cancer of the thyroid, the most common adverse
events typically occurred early and were primarily managed
with dose modiﬁcations. Overall survival was signiﬁcantly
associated with diarrhea.
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Introduction
Multikinase inhibitors, including those with antiangiogenic
properties, have been increasingly positioned as the stan-
dard therapy either alone or in combination with other
therapeutic agents for the treatment of multiple tumor types
[1, 2]. Although the majority of antiangiogenic treatments
are well tolerated, and toxicities are manageable with dose
modiﬁcations, these agents are associated with distinct
adverse events (AEs) because of their effect on tumors and
the surrounding vasculature as well as on normal tissues [3].
Given the rapid expansion of these agents in clinical use,
awareness of common toxicities and management is para-
mount, with the goal of providing optimal therapy for the
patient.
Lenvatinib is an oral multikinase inhibitor of vascular
endothelial growth factor receptor (VEGFR) 1–3, ﬁbroblast
growth factor receptor 1–4, platelet derived growth factor
receptor α (PDGFRα), and RET and KIT proto-oncogenes
[4–6]. Lenvatinib was recently approved for the treatment
of radioiodine-refractory differentiated thyroid cancer (RR-
DTC) in the United States, Europe, and Japan [7, 8], based
on results from the pivotal phase 3 study of (E7080) len-
vatinib in differentiated cancer of the thyroid (SELECT),
where lenvatinib signiﬁcantly prolonged progression-free
survival (PFS) vs. placebo (median PFS: 18.3 vs.
3.6 months; hazard ratio [HR]: 0.21; 99% conﬁdence
interval [CI]: 0.14–0.31; P < 0.001) [9].
In SELECT, nearly all of the 392 patients enrolled
experienced an AE. A large proportion of lenvatinib-treated
patients required dose reduction (68%) or interruption
(82%) due to treatment-emergent adverse events (TEAEs),
but few required discontinuation (14%) of lenvatinib treat-
ment due to TEAEs [9]. We had previously reported an
analysis of lenvatinib-emergent hypertension—the most
common AE in SELECT—its management, and correla-
tions with efﬁcacy from SELECT [10]. This current ana-
lysis examines the incidences, time course, and resolution of
other clinically important and common lenvatinib-emergent
AEs from SELECT—namely diarrhea, fatigue/asthenia/
malaise, proteinuria, rash, and palmar-plantar ery-
throdysesthesia syndrome (PPES), and the relationship
between these AEs and survival outcomes.
Patients and methods
Patients and study design
Full details of the SELECT methodology have been pre-
viously published [9]. Brieﬂy, in this phase 3, randomized,
double-blind, multicenter study, patients with RR-DTC and
measurable disease per Response Evaluation Criteria in
Solid tumors version 1.1 and independently reviewed
radiologic evidence of disease progression within
13 months prior to study entry were enrolled. Patients could
have received up to 1 prior VEGF-targeted therapy, and
patients with proteinuria ≥1 g/24 h were excluded from the
study. Eligible patients were stratiﬁed according to geo-
graphic region, age group, and prior VEGF-targeted treat-
ment, and were randomized in a 2:1 ratio to receive oral
doses of lenvatinib (24 mg once daily) or placebo in 28-day
continuous cycles. Study treatment was administered until
disease progression, development of unacceptable toxi-
cities, or withdrawal of consent. A total of 392 patients
enrolled (200 male and 192 female). 261 Patients were
assigned to lenvatinib (125 male and 136 female) and 131
patients were assigned placebo (75 male and 56 female).
This study was conducted in accordance with the
declaration of Helsinki and local laws. informed consent
was obtained from all individual participants included in the
study and the protocol was approved by all relevant insti-
tutional review bodies.
Safety evaluation and treatment modiﬁcations
Safety assessments in SELECT included recording and
monitoring all AEs and serious AEs, vital signs, clinical
laboratory tests (hematology, clinical chemistry, urine
values), and electrocardiograms. AEs were assessed based
on the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 4.0 and coded
according to the Medical Dictionary for Regulatory Activ-
ities version 16.0. In this analysis, all TEAEs were con-
sidered, regardless of clinical investigator-assessed
relationship to study drug. Additionally, colitis, bowel
movement irregularity, frequent bowel movements, func-
tional gastrointestinal disorder, gastrointestinal disorder,
and change in bowel habit were grouped together under
diarrhea. Similarly, macule, papule, rash erythematous, rash
generalized, rash macular, rash maculopapular, rash papu-
lar, and rash pruritic were included together under rash.
Lenvatinib dose interruptions for TEAEs of intolerable
grade 2 or grade 3 were allowed until the events resolved to
grade <1 or baseline, then sequential lenvatinib dose
reductions (20 mg to 14 mg, then to 10 mg) were imple-
mented. Patients discontinued treatment upon occurrence of
a grade 4 TEAE, except for grade 4 laboratory abnormal-
ities, which were treated as grade 3 events. Additionally,
there was a speciﬁc monitoring plan for proteinuria, which
was tested for at regular assessments during scheduled
visits. During the randomization phase, patients with con-
ﬁrmed proteinuria based on a urine dipstick reading of
≥2+ were tested, at minimum, every 2 weeks until results
were 1+ or negative for 3 consecutive months. Any sub-
sequent proteinuria reading of ≥ 2+ by urine dipstick
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were assessed for AE grade and managed with dose
modiﬁcations.
Statistical analysis
The primary analysis data cutoff date for this study was 15
November 2013, and all enrolled patients who received any
amount of lenvatinib or placebo in the randomization phase
were included in the safety analysis. The time to onset of
TEAEs were summarized using time-to-event analyses
for median time to ﬁrst onset, and descriptive statistics for
cycle of ﬁrst occurrence. Correlations between common
TEAEs and efﬁcacy endpoints (PFS and overall survival
[OS]) were ﬁrst analyzed using a Cox-proportional hazards
model in univariate analyses, where factors with a P< 0.2
were further included in a multivariate model with addi-
tional variables (baseline Eastern Cooperative Oncol-
ogy Group performance status [ECOG PS], previous
VEGF-targeted therapy, baseline weight, age, region [Eur-
ope vs. Other], region [North America vs. Other], and his-
tology [follicular vs. papillary thyroid cancer]). Sex was not
considered a factor in this analysis.
Results
Frequency and time course of TEAEs
Of the 392 patients enrolled in SELECT, 261 received
lenvatinib and 131 received placebo. All enrolled patients
were included in the safety analysis. Incidence of treatment-
related adverse events in SELECT was previously reported
[9]. Overall, any-grade TEAEs (regardless of investigator-
assessed relationship to study drug) occurred in 100% of
lenvatinib-treated patients and 90% of placebo-treated
patients. Grade 3 TEAEs occurred in 72% of lenvatinib-
treated patients and 22% of placebo-treated patients,
whereas grade 4 TEAEs occurred in 12% of lenvatinib-
treated patients and 8% of placebo-treated patients.
Following hypertension, the most common TEAEs in
lenvatinib-treated patients vs. placebo-treated patients
included diarrhea (67% vs. 17%), fatigue/asthenia/malaise
(67% vs. 35%), proteinuria (32% vs. 3%), rash (23% vs.
5%), and PPES (33% vs. 1%). The incidences of these
common TEAEs, by grade 1–2 and grade 3, are described in
Table 1. Importantly, there were no grade 4 events for any
of these 5 TEAEs.
The median time to ﬁrst onset of any-grade TEAE was
12.1 weeks (interquartile range [IQR]: 4.1–23.7 weeks) for
diarrhea, 3.0 weeks (IQR: 1.1–7.0 weeks) for fatigue/asth-
enia/malaise, 6.1 weeks (IQR: 4.0–15.6 weeks) for protei-
nuria, 7.3 weeks (IQR: 2.9–16.3 weeks) for rash, and
5.9 weeks (IQR: 3.1–12.0 weeks) for PPES in lenvatinib-
treated patients. Generally, the frequencies of these TEAEs
were higher in the earlier cycles of treatment and dimin-
ished over the course of treatment (Fig. 1). In cycle 1 of
lenvatinib treatment, 16% of patients experienced diarrhea,
42% experienced fatigue/asthenia/malaise, 9% had protei-
nuria, 7% had rash, and 11% had PPES. In cycle 2 of
lenvatinib treatment, 8% of patients had diarrhea, 9% had
fatigue/asthenia/malaise, 8% had proteinuria, 5% had rash,
and 10% had PPES. By cycle 6 of lenvatinib treatment, the
frequencies of most TEAEs had reduced to ≤ 4%, with the
exception of diarrhea at cycle 11 (9%). Overall, the fre-
quencies of grade 3 events of these 5 TEAEs were low (<
4%) across treatment cycles Fig. 2.
Management of TEAEs
Overall, TEAEs led to dose reductions or interruptions in
89% of the patients treated with lenvatinib in SELECT. In
particular, these 5 common TEAEs were managed with
supportive care, dose modiﬁcations, and, when necessary,
concomitant medications (Table 2). Dose reductions and








Median time to ﬁrst
onset, weeks (IQR)
Median time to last
resolution, weeks (IQR)
Diarrheaa 152 (58) 23 (9) 12.1 (4.1, 23.7) 18.1 (2.3, 40.9)
Fatigue/asthenia/malaise 147 (56) 27 (10) 3.0 (1.1, 7.0) 16.3 (4.6, 36.6)
Proteinuria 58 (22) 26 (10) 6.1 (4.0, 15.6) 8.8 (4.0, 24.6)
Rashb 58 (22) 1 (0) 7.3 (2.9, 16.3) 5.9 (2.0, 18.6)
PPES 76 (29) 9 (3) 5.9 (3.1, 12.0) 20.0 (8.6, 32.1)
IQR, interquartile range, PPES, palmar-plantar erythrodysesthesia syndrome
a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional
gastrointestinal disorder, gastrointestinal disorder, and change in bowel habit
b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash
papular, and rash pruritic
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Fig. 2 Cycle of ﬁrst occurrence of grade 3 adverse events
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dose interruptions due to these TEAEs occurred in 1 to 13%
and 0 to 18% of lenvatinib-treated patients, respectively,
and only 6 patients discontinued lenvatinib treatment due to
these TEAEs (4 patients with fatigue/asthenia/malaise and 2
patients with proteinuria). The median time to last resolu-
tion of each TEAE was 18.1 weeks (IQR: 2.3–40.9 weeks)
for diarrhea, 16.3 weeks (IQR: 4.6–36.6 weeks) for fatigue/
asthenia/malaise, 8.8 weeks (IQR: 4.0–24.6 weeks) for
proteinuria, 5.9 weeks (IQR: 2.0–18.6 weeks) for rash, and
20.0 weeks (IQR: 8.6–32.1 weeks) for PPES in lenvatinib-
treated patients.
TEAEs and associations with efﬁcacy
Based on results of univariate analyses, out of the ﬁve
examined TEAEs, only PPES (P= 0.08) was further
included in a multivariate model for associations with PFS
(Table 3). However, no signiﬁcant association was found
between lenvatinib-treated patients with PPES (P= 0.178)
and PFS. The only signiﬁcant association with PFS in the
multivariate model was for baseline ECOG PS (favoring
ECOG PS of 0 vs. ≥1; HR: 0.51; 95% CI: 0.34–0.76;
P= 0.0008).
Table 2 Management of common adverse events

















Diarrheaa 27 (10) 0 46 (18) 0 0 0 111 (43) 8 (6)
Fatigue/asthenia/malaise 35 (13) 1 (0.8) 42 (16) 3 (2) 4 (2) 0 4 (2) 0
Proteinuria 28 (11) 0 42 (16) 0 2 (1) 0 2 (1) 0
Rashb 3 (1) 0 1 (0) 1 (1) 0 0 22 (8) 1 (1)
PPES 20 (8) 0 26 (10) 0 0 0 44 (17) 0
LEN, lenvatinib, PBO, placebo, PPES, palmar-plantar erythrodysesthesia syndrome
a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional gastrointestinal disorder, gastrointestinal disorder,
and change in bowel habit
b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash papular, and rash pruritic
Table 3 Univariate and
multivariate analyses for
progression-free survival
Variables Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Fatigue/asthenia/malaise 1.16 0.75–1.78 0.509
Diarrheaa 0.94 0.61–1.46 0.784
PPES 1.49 0.95–2.33 0.084 1.35 0.87–2.08 0.178
Rashb 1.2 0.72–2.00 0.495
Proteinuria 1.3 0.82–2.07 0.259
Baseline ECOG PS (0 vs. ≥1) 0.51 0.34–0.76 0.0008
Prior VEGF therapy (0 vs. 1) 0.86 0.55–1.33 0.487
Baseline weight (kg) 0.99 0.98–1.00 0.078
Age (years) 1.02 1.00–1.04 0.084
Region (Europe vs. Other) 1.37 0.78–2.42 0.274
Region (North America vs. Other) 1.13 0.57–2.23 0.724
Histology (Follicular vs. papillary) 0.67 0.44–1.02 0.062
CI, conﬁdence interval, ECOG PS, Eastern Cooperative Oncology Group performance status, HR, hazard
ratio, PPES, palmar-plantar erythrodysesthesia syndrome, VEGF, vascular endothelial growth factor
a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional
gastrointestinal disorder, gastrointestinal disorder, and change in bowel habit
b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash
papular, and rash pruritic
Endocrine (2017) 56:121–128 125
For associations with OS, of the ﬁve examined TEAEs,
only diarrhea (P= 0.012 in the univariate analysis) was
further included as a variable in the multivariate model
(Table 4). In the model, treatment-emergent diarrhea was
found to be signiﬁcantly associated with OS (yes vs. no;
HR: 0.55; 95% CI: 0.33–0.92; P= 0.023), along with
baseline ECOG PS (favoring ECOG PS of 0 vs. ≥1; HR:
0.44; 95% CI: 0.27–0.73; P= 0.001), and histology
(favoring follicular vs. papillary thyroid cancer; HR: 0.36;
95% CI: 0.19–0.68; P= 0.002). The median OS for
lenvatinib-treated patients who experienced diarrhea had
not yet been reached at the time of data cutoff; however, for
those patients who did not experience diarrhea, the median
OS was 17.1 months (95% CI: 10.8–22.1).
Discussion
In the phase 3 pivotal study of lenvatinib in patients with
RR-DTC, lenvatinib met its primary endpoint and sig-
niﬁcantly improved PFS compared with placebo (18.3 and
3.6 months, respectively; HR: 0.21; 99% CI: 0.14–0.31;
P< 0.001) [9]. The response rate with lenvatinib was also
substantially improved (65% vs. 2% for placebo) [9]. At the
time of the primary data cutoff (15 November 2013), the
median duration of objective response had not been
reached. In an updated analysis of response (data cutoff 31
August 2015), the median duration of objective response
was 30 months (95% CI: 18.4–35.2) for lenvatinib and
14.7 months (95% CI 7.5–not evaluable) for placebo [11].
In an updated analysis of OS (updated data cutoff 15 June
2014) using a rank-preserving, structural-failure–time
model to adjust for crossover, the HR for OS was 0.53; 95%
CI: 0.34–0.82, with a nominal bootstrapped P= 0.0051.
The median OS for lenvatinib still had not been reached,
and was 19.1 months for placebo [12].
Similar to other established VEGF-targeted therapies for
cancer, lenvatinib is associated with AEs that are distinct
from cytotoxic treatment options [13, 14]. VEGF or
VEGFR inhibitors are largely well-tolerated, and patients on
these agents are less likely to discontinue treatment com-
pared with cytotoxic therapies; however, with the chronic
use of any agent, there may be the need for additional
vigilance of side effects [15]. In addition, given the overall
poor physical conditions of patients with advanced disease,
clinicians should be prepared to monitor and manage AEs
appropriately in order to improve or maintain patients’
quality of life [13]. Early assessment of AEs is particularly
important so that early intervention can be implemented and
patients can remain on treatment.
In the phase three SELECT study, toxicities were com-
mon, with almost all patients reporting a TEAE (lenvatinib,
100%; placebo, 90%). The most common TEAE was
hypertension, which has been examined in a separate ana-
lysis [10]. In this analysis, the ﬁve common lenvatinib-
emergent AEs proﬁled (diarrhea, fatigue/asthenia/malaise,
proteinuria, rash, and PPES) typically occurred early—
within the ﬁrst 2 months of initiating therapy—and dimin-
ished over the course of treatment. The incidence of diar-
rhea was the highest during the ﬁrst cycle, relatively stable
Table 4 Univariate and
multivariate analyses for overall
survival
Variables Univariate analysis Multivariate analysis
HR 95% CI P-value HR 95% CI P-value
Fatigue/asthenia/malaise 0.9 0.53–1.51 0.687
Diarrheaa 0.5 0.29–0.86 0.012 0.55 0.33–0.92 0.023
PPES 0.72 0.40–1.30 0.276
Rashb 0.77 0.39–1.52 0.449
Proteinuria 1.22 0.71–2.10 0.477
Baseline ECOG PS (0 vs. ≥ 1) 0.44 0.27–0.73 0.001
Prior VEGF therapy (0 vs. 1) 0.68 0.4–1.15 0.151
Baseline weight (kg) 0.99 0.98–1.00 0.174
Age (years) 1.01 0.98–1.03 0.64
Region (Europe vs. Other) 0.92 0.49–1.74 0.806
Region (North America vs. Other) 0.75 0.34–1.63 0.462
Histology (Follicular vs. papillary) 0.36 0.19–0.68 0.002
CI, conﬁdence interval, ECOG PS, Eastern Cooperative Oncology Group performance status, HR, hazard
ratio, PPES, palmar-plantar erythrodysesthesia syndrome, VEGF, vascular endothelial growth factor
a Includes diarrhea, colitis, bowel movement irregularity, frequent bowel movements, functional
gastrointestinal disorder, gastrointestinal disorder, and change in bowel habit
b Includes macule, papule, rash, rash erythematous, rash generalized, rash macular, rash maculopapular, rash
papular, and rash pruritic
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between cycles two and ﬁve of lenvatinib treatment, and
then decreased thereafter. Similarly, the frequency of fati-
gue/asthenia/malaise was highest during cycle one but was
drastically reduced by cycle two onward. While clinicians
should consider lenvatinib treatment for patients with pro-
gressive RR-DTC, it is important that preexisting conditions
be adequately controlled before treatment. This is especially
true for patients with preexisting hypertension, as this is the
most common lenvatinib-emergent AE. However, in certain
other settings, such as in patients with high risk for tra-
cheoesophogeal ﬁstula or bowel rupture, or in those already
severely cachectic, any anti-angiogenic tyrosine kinase
inhibitor therapy such as lenvatinib may be relatively
contraindicated.
This general timing of AEs is similar to that found with
other VEGF inhibitors [16], and may indicate that, for at
least some of the AEs—for example, fatigue—symptoms
may be self-limiting. Although it is unclear why the timing
of these AEs follows such a pattern, it would be prudent to
note that response to lenvatinib treatment is typically
characterized by a rapid initial tumor size reduction (median
change –25% by the ﬁrst tumor assessment at 8 weeks),
followed by slower but continuous shrinkage [17]. The
magnitude of this reduction has been correlated to lenvati-
nib exposure during the ﬁrst 8 weeks of treatment, which is
also the period with the highest incidences of these proﬁled
AEs. It is also possible that there is a reporting bias, and that
reports of these AEs diminish over time as patients become
accustomed to living with the symptoms. These ﬁndings
altogether underscore the importance of timely and appro-
priate AE management by the treating physician, in order to
maximize potential treatment beneﬁt to the patients.
In previous studies of VEGF/R inhibitors, including
sorafenib [18] and sunitinib [19], speciﬁc AEs were found
to be predictive of superior survival outcome in patients
with metastatic renal cell carcinoma. In SELECT, patients
with lenvatinib-emergent hypertension may have a PFS
advantage compared with patients treated with lenvatinib
who did not experience hypertension [10]. In this current
study, the occurrence of diarrhea, along with baseline
ECOG PS and histology were identiﬁed as predictive
factors for OS, whereas no examined AE in this analysis
was predictive of PFS. It is important to note, however,
that these analyses were exploratory in nature, and that
there is no speciﬁc biologic hypothesis for an association
between diarrhea and OS—diarrhea may be a pharmaco-
dynamic marker, or the association may simply be one
of chance.
In conclusion, these common TEAEs from SELECT—
diarrhea, fatigue/asthenia/malaise, proteinuria, rash, and
PPES―were manageable with dose modiﬁcations and sup-
portive care, and very few patients discontinued lenvatinib
treatment as a result of these events. The ﬁndings of this
analysis thus provide insight regarding the need for proac-
tive management of toxicities during lenvatinib adminis-
tration, particularly after initiation of therapy, to maximize
treatment beneﬁt for the patient.
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